Lung Cancer Considered podkast

ESMO 2026 Highlights – Part 1

0:00
1:26:37
Do tyłu o 15 sekund
Do przodu o 15 sekund
In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice. Jaruska Naidoo, MD Professor of Medical Oncology Royal College of Surgeons Consultant, Medical Oncologist at Beaumont Hospital X: @DrJNaidoo Instagram: jarushkanaidoo LinkedIn: https://www.linkedin.com/in/jarushka-naidoo-127a3b97/ Jacob Sands, MD Assistant Professor of Medicine, Harvard Medical School Associate Chief, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute X: @sands_jacob Instagram: jacobsands LinkedIn: https://www.linkedin.com/in/jacobsands/ Ferdinandos Skoulidis, MD, PhD Professor, Department of Thoracic and Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center

Więcej odcinków z kanału "Lung Cancer Considered"